| Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, invariably fatal neurological disease. Individuals impacted by ALS include those living with the disease, their caregivers, and presymptomatic individuals at risk for developing ALS. Currently no treatments are available to stop or reverse the disease, although various FDA-approved formulations may extend life by several months The National Academies ad hoc committee, “Amyotrophic Lateral Sclerosis: Accelerating Treatments and Improving Quality of Life,” will hold a virtual public workshop series to examine key actions the public, private, and nonprofit sectors should take to make ALS a livable disease within the next decade.
Workshop #1 on August 10, 2023, will consider the type/range of care and services people with ALS and their families need, and how to ensure they receive that care.
Workshop #2 on August 23, 2023, will allow people living with ALS, caregivers, and individuals at genetic risk of developing ALS the chance to engage with the committee on various topics related to their quality of life, health, and well-being.
Workshop #3 on September 1, 2023, will explore current ALS research and therapeutic development efforts.
All workshops will be held via live webcast. |
